O	0	11	Biophysical
O	12	16	skin
O	17	29	measurements
O	30	32	to
O	33	41	evaluate
O	42	45	the
O	46	59	effectiveness
O	60	62	of
B-intervention	63	81	photobiomodulation
I-intervention	82	89	therapy
O	90	92	in
O	93	96	the
O	97	107	prevention
O	108	110	of
B-condition	111	116	acute
I-condition	117	126	radiation
I-condition	127	137	dermatitis
O	138	140	in
O	141	147	breast
O	148	154	cancer
O	155	163	patients
O	163	164	.

O	165	168	The
O	169	176	purpose
O	177	179	of
O	180	184	this
O	185	190	study
O	191	194	was
O	195	197	to
O	198	206	evaluate
O	207	218	objectively
O	219	222	the
O	223	236	effectiveness
O	237	239	of
O	240	258	photobiomodulation
O	259	266	therapy
O	267	268	(
O	268	272	PBMT
O	272	273	)
O	274	277	for
O	278	281	the
O	282	292	prevention
O	293	295	of
O	296	301	acute
O	302	311	radiation
O	312	322	dermatitis
O	323	324	(
O	324	327	ARD
O	327	328	)
O	329	331	by
O	332	337	using
O	338	349	biophysical
O	350	354	skin
O	355	367	measurements
O	367	368	.

O	369	370	A
O	371	381	randomized
O	381	382	,
O	383	390	placebo
O	390	391	-
O	391	401	controlled
O	402	407	trial
O	408	412	with
B-total-participants	413	416	120
B-eligibility	417	423	breast
I-eligibility	424	430	cancer
I-eligibility	431	439	patients
I-eligibility	440	443	who
I-eligibility	444	453	underwent
I-eligibility	454	456	an
I-eligibility	457	466	identical
I-eligibility	467	479	radiotherapy
I-eligibility	480	481	(
I-eligibility	481	483	RT
I-eligibility	483	484	)
I-eligibility	485	492	regimen
I-eligibility	493	497	post
I-eligibility	497	498	-
I-eligibility	498	508	lumpectomy
O	509	512	was
O	513	522	performed
O	523	524	(
O	524	535	TRANSDERMIS
O	536	541	trial
O	541	542	)
O	542	543	.

O	544	552	Patients
O	553	557	were
O	558	568	randomized
O	569	571	to
O	572	579	receive
O	580	583	PBM
O	584	585	(
O	585	588	808
O	589	591	nm
O	592	594	CW
O	594	595	/
O	595	598	905
O	599	601	nm
O	602	608	pulsed
O	608	609	,
O	610	613	168
O	614	616	mW
O	616	617	/
O	617	620	cm2
O	620	621	,
O	622	626	spot
O	627	631	size
O	632	634	19
O	634	635	.
O	635	636	6
O	637	640	cm2
O	640	641	,
O	642	649	fluence
O	650	651	4
O	652	653	J
O	653	654	/
O	654	657	cm2
O	657	658	)
O	659	661	or
B-control	662	669	placebo
O	670	680	treatments
O	681	685	from
O	686	689	the
O	690	695	first
O	696	699	day
O	700	702	of
O	703	705	RT
O	706	707	(
O	707	708	2
O	708	709	Ã—
O	709	710	/
O	710	714	week
O	714	715	)
O	715	716	.

O	717	728	Biophysical
O	729	733	skin
O	734	746	measurements
O	747	751	were
O	752	761	collected
O	762	764	to
O	765	771	assess
O	772	775	the
O	776	780	skin
O	781	793	pigmentation
O	794	797	and
O	798	805	barrier
O	806	814	function
O	814	815	.

O	816	828	Measurements
O	829	833	were
O	834	843	collected
O	844	846	at
O	847	850	the
O	851	856	first
O	857	860	day
O	861	863	of
O	864	866	RT
O	866	867	,
O	868	869	a
O	870	872	RT
O	873	877	dose
O	878	880	of
O	881	883	40
O	884	888	Gray
O	889	890	(
O	890	892	Gy
O	892	893	)
O	893	894	,
O	895	898	and
O	899	902	the
O	903	906	end
O	907	909	of
O	910	912	RT
O	913	914	(
O	914	916	66
O	917	919	Gy
O	919	920	)
O	920	921	.

O	922	925	The
B-outcome	926	935	incidence
I-outcome	936	938	of
I-outcome	939	944	moist
I-outcome	945	957	desquamation
O	958	961	was
O	962	975	significantly
O	976	982	higher
O	983	985	in
O	986	989	the
O	990	997	control
O	998	1002	than
O	1003	1005	in
O	1006	1009	the
O	1010	1014	PBMT
O	1015	1020	group
O	1021	1023	at
O	1024	1027	the
O	1028	1031	end
O	1032	1034	of
O	1035	1037	RT
O	1038	1039	(
B-cv-bin-percent	1039	1041	30
O	1042	1044	vs
O	1044	1045	.
B-iv-bin-percent	1046	1047	7
I-iv-bin-percent	1047	1048	%
O	1048	1049	,
O	1050	1062	respectively
O	1062	1063	,
O	1064	1068	odds
O	1069	1074	ratio
O	1075	1076	=
O	1077	1078	6
O	1078	1079	,
O	1080	1081	p
O	1082	1083	=
O	1084	1085	0
O	1085	1086	.
O	1086	1089	004
O	1089	1090	)
O	1090	1091	.

O	1092	1095	The
O	1096	1107	biophysical
O	1108	1112	skin
O	1113	1121	measures
O	1122	1128	showed
O	1129	1133	that
O	1134	1137	the
O	1138	1142	mean
O	1143	1153	percentage
O	1154	1160	change
O	1161	1165	from
O	1166	1169	the
O	1170	1178	baseline
B-outcome	1179	1193	transepidermal
I-outcome	1194	1199	water
I-outcome	1200	1204	loss
I-outcome	1205	1206	(
I-outcome	1206	1210	TEWL
I-outcome	1210	1211	)
O	1211	1212	,
B-outcome	1213	1221	erythema
O	1221	1222	,
O	1223	1226	and
B-outcome	1227	1234	melanin
I-outcome	1235	1241	values
O	1242	1245	was
O	1246	1259	significantly
O	1260	1266	higher
O	1267	1269	in
O	1270	1273	the
O	1274	1281	control
O	1282	1286	than
O	1287	1289	in
O	1290	1293	the
O	1294	1298	PBMT
O	1299	1304	group
O	1305	1307	at
O	1308	1311	the
O	1312	1315	end
O	1316	1318	of
O	1319	1321	RT
O	1322	1323	(
O	1323	1325	ps
O	1326	1327	<
O	1328	1329	0
O	1329	1330	.
O	1330	1332	05
O	1332	1333	)
O	1333	1334	.

O	1335	1343	Logistic
O	1344	1354	regression
O	1355	1363	analysis
O	1364	1372	revealed
O	1373	1377	that
O	1378	1381	the
O	1382	1386	risk
O	1387	1389	on
B-outcome	1390	1395	moist
I-outcome	1396	1408	desquamation
O	1409	1412	was
O	1413	1426	significantly
O	1427	1436	increased
O	1437	1440	for
O	1441	1449	patients
O	1450	1454	with
O	1455	1456	a
O	1457	1462	large
O	1463	1464	(
O	1464	1465	>
O	1466	1469	800
O	1470	1472	cc
O	1472	1473	)
O	1474	1480	breast
O	1481	1487	volume
O	1488	1489	(
O	1489	1493	odds
O	1494	1499	ratio
O	1500	1501	=
O	1502	1503	4
O	1503	1504	,
O	1505	1506	p
O	1507	1508	=
O	1509	1510	0
O	1510	1511	.
O	1511	1514	017
O	1514	1515	)
O	1515	1516	.

O	1517	1521	This
O	1522	1524	is
O	1525	1528	the
O	1529	1534	first
O	1535	1545	randomized
O	1546	1556	controlled
O	1557	1562	trial
O	1563	1576	demonstrating
O	1577	1579	by
O	1580	1589	objective
O	1590	1602	measurements
O	1603	1607	that
O	1608	1612	PBMT
O	1613	1615	is
O	1616	1625	effective
O	1626	1628	in
O	1629	1637	reducing
O	1638	1641	the
O	1642	1651	incidence
O	1652	1654	of
O	1655	1660	moist
O	1661	1673	desquamation
O	1674	1676	in
O	1677	1683	breast
O	1684	1690	cancer
O	1691	1699	patients
O	1700	1710	undergoing
O	1711	1713	RT
O	1713	1714	.

O	1715	1727	Additionally
O	1727	1728	,
O	1729	1730	a
O	1731	1736	large
O	1737	1743	breast
O	1744	1750	volume
O	1751	1753	is
O	1754	1756	an
O	1757	1766	important
O	1767	1771	risk
O	1772	1778	factor
O	1779	1782	for
O	1783	1786	the
O	1787	1798	development
O	1799	1801	of
O	1802	1807	moist
O	1808	1820	desquamation
O	1820	1821	.
